Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
1 clinical trials · Condition
◉ Watch Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery
| Record | Firm | Date |
|---|---|---|
| HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis (NCT04889768) | Zhejiang Cancer Hospital | 2021-07-31 |
Track Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery automatically
Every clearance here is in the API, with alerts when new ones post.